Yingying Cui

Yingying Cui

Auto-generated profile, based on publicly available information

Yingying Cui

Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XLXin Li
Xin Li
YCYingying Cui
Yingying Cui
ZSZhenchang Sun
Zhenchang Sun
LZLei Zhang
Lei Zhang
LLLing Li
Ling Li
MZMingzhi Zhang
Mingzhi Zhang
Purpose: Optimal treatment strategies for advanced natural killer/T (NK/T)-cell lymphoma have not been fully defined. We compared the safety and efficacy of DDGP and SMILE regimens for advanced NK/T-cell lymphoma in a randomized controlled, multicenter, and open-label clinical trial. Experimental Design: Patients were newly diagnosed in stages III–IV and had performance scores in 0 to 2. Six cycles of DDGP (dexamethasone, cisplatin, gemcitabline, and pegaspargase) or SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy were randomly assigned to them. The primary end point was progression-free survival (PFS). Secondary end points included response rate and overall survival (OS). The trial is ongoing and is registered with ClinicalTrials.gov (No. NCT01501149). Results: Of 42 patients enrolled, 21 were treated with DDGP therapy, and 21 patients were treated with SMILE therapy. The 1-year PFS and 2-year OS rates were better in the DDGP group than that in the SMILE group (86% vs. 38% for 1-year PFS, P = 0.006; 74% vs. 45% for 2-year OS, P = 0.027). Complete remission (CR) rate and overall response rate (ORR) of the DDGP group were higher than that in the SMILE group (71% vs. 29%, P = 0.005 for CR rate; 95% vs. 67%, P = 0.018 for ORR). The SMILE group showed more serious leucopenia (P = 0.030) and severe allergic reaction (P = 0.015) than the DDGP group. In addition, two cases in the SMILE group underwent grade 4 mucosal reaction. Conclusions: DDGP chemotherapy resulted in significant improvement in PFS, OS, and better tolerability compared with SMILE chemotherapy for newly diagnosed advanced NK/T-cell lymphoma patients. Clin Cancer Res; 22(21); 5223–8. ©2016 AACR.

17 November 2015 in Oncology Reports
Verified
Journal Article
Closed access
CLChangsen Leng
Changsen Leng
YLYin Li
Yin Li
JQJianjun Qin
Jianjun Qin
JMJun Ma
Jun Ma
XLXianben Liu
Xianben Liu
QWQiuming Wang
Qiuming Wang
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

22 March 2020 in Cells
Verified
Journal Article
Open access
PDF file
YCYingying Cui
Yingying Cui
MZMengfan Zhang
Mengfan Zhang
CLChangsen Leng
Changsen Leng
TBT. Blokzijl
T. Blokzijl
BJBernadien H. Jansen
Bernadien H. Jansen
KFKlaas Nico Faber
Klaas Nico Faber
Intestinal fibrosis is a common complication of inflammatory bowel disease. So far, there is no safe and effective drug for intestinal fibrosis. Pirfenidone is an anti-fibrotic compound available for the treatment of idiopathic pulmonary fibrosis. Here, we explored the anti-proliferative and anti-fibrotic properties of pirfenidone on primary human intestinal fibroblasts (p-hIFs). p-hIFs were cultured in the absence and presence of pirfenidone. Cell proliferation was measured by a real-time cell analyzer (xCELLigence) and BrdU incorporation. Cell motility was monitored by live cell imaging. Cytotoxicity and cell viability were analyzed by Sytox green, Caspase-3 and Water Soluble Tetrazolium Salt-1 (WST-1) assays. Gene expression of fibrosis markers was determined by quantitative reverse transcription PCR (RT-qPCR). The mammalian target of rapamycin (mTOR) signaling was analyzed by Western blotting and type I collagen protein expression additionally by immunofluorescence microscopy. Pirfenidone dose-dependently inhibited p-hIF proliferation and motility, without inducing cell death. Pirfenidone suppressed mRNA levels of genes that contribute to extracellular matrix production, as well as basal and TGF-β1-induced collagen I protein production, which was associated with inhibition of the rapamycin-sensitive mTOR/p70S6K pathway in p-hIFs. Thus, pirfenidone inhibits the proliferation of intestinal fibroblasts and suppresses collagen I production through the TGF-β1/mTOR/p70S6K signaling pathway, which might be a novel and safe anti-fibrotic strategy to treat intestinal fibrosis.

30 December 2014 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
ZZZhiyuan Zhou
Zhiyuan Zhou
CCChangying Chen
Changying Chen
XLXiang Li
Xiang Li
ZLZhaoming Li
Zhaoming Li
XZXudong Zhang
Xudong Zhang
MZMingzhi Zhang
Mingzhi Zhang

6 July 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
ZSZhenchang Sun
Zhenchang Sun
KHKai Huang
Kai Huang
XFXiaorui Fu
Xiaorui Fu
ZZZhiyuan Zhou
Zhiyuan Zhou
YCYingying Cui
Yingying Cui
HLHaopeng Li
Haopeng Li

20 November 2015 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
YCYingying Cui
Yingying Cui
ZSZhenchang Sun
Zhenchang Sun
XLXin Li
Xin Li
CLChangsen Leng
Changsen Leng
LZLei Zhang
Lei Zhang
YMYaozhen Ma
Yaozhen Ma
Cyclooxygenase‑2 (COX‑2) and interleukin‑32 (IL‑32) expression has been examined in various carcinomas and inflammations, and has been suggested to be significant in tumor progression and prognosis. The present study was conducted to investigate the expression of COX‑2 and IL‑32 in primary gastric B‑cell lymphoma in order to define their clinical significance and their association with Helicobacter pylori (Hp) infection. COX‑2 and IL‑32 protein expression was detected in 31 primary gastric B‑cell lymphoma patients and 19 chronic gastritis patients with immunohistochemistry. COX‑2 and IL‑32 expression was significantly higher in primary gastric lymphoma (PGL) tissues compared with gastritis tissues (51.6 vs. 21.1% for COX‑2, P=0.032; and 58.1 vs. 26.3% for IL‑32, P=0.029) and was significantly higher in Hp+ lymphoma tissues compared with Hp‑ lymphoma tissues (66.7 vs. 20% for COX‑2, P=0.015; and 71.4 vs. 30% for IL‑32, P=0.029). In the PGL tissues, the expression level of COX‑2 was positively correlated with the expression level of IL‑32, and the two were each positively correlated with Hp infection (P=0.004 for COX‑2 and IL‑32; P=0.01 for COX‑2 and Hp infection; and P=0.003 for IL‑32 and Hp infection). COX‑2 expression was found to be significantly associated (P<0.05) with an aggressive tumor type, higher expression of Ki‑67, frequent lymph node metastasis and advanced stage. IL‑32 expression was found to be significantly correlated (P<0.05) with frequent lymph node metastasis and an advanced stage. The survival time was longer in the COX‑2‑ and IL‑32‑ lymphoma patients compared with the COX‑2+ and IL‑32+ lymphoma patients, but these differences were not statistically significant. These results suggested that Hp infection and the expression of COX‑2 and IL‑32 were closely linked with each other, and that the overexpression of COX‑2 and IL‑32 was correlated with tumor progression in primary gastric B‑cell lymphoma, thus indicating potential novel therapeutic target.